Gene expression profiling identifies markers of ampullary adenocarcinoma

Cancer Biology and Therapy

Volumn 3, Issue 7, 2004, Pages 651-656

  Van Heek, N Tjarda ^a,e   Maitra, Anirban ^a   Koopmann, Jens ^a   Fedarko, Neil ^b   Jain, Alka ^b   Rahman, Ayman ^a   Iacobuzio Donahue, Christine A ^a   Adsay, Volkan ^c   Ashfaq, Raheela ^d   Yeo, Charles J ^a   Cameron, John L ^a   Offerhaus, Johan A ^e   Hruban, Ralph H ^a   Berg, Karin D ^a   Goggins, Michael ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Ampullary cancer; Microarray; Osteopontin

Indexed keywords

FASCIN; FIBRONECTIN; FIBRONECTIN 1; HEAT SHOCK PROTEIN 47; MESOTHELIN PROTEIN; MUCIN; MUCIN 1; MUCIN 5; OSTEOPONTIN; PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; SIALOGLYCOPROTEIN; SPP1 PROTEIN, HUMAN; TUMOR MARKER;

ADENOMA; ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DUODENUM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MEASUREMENT; PREOPERATIVE EVALUATION; PROTEIN BLOOD LEVEL; SAMPLE; TISSUE MICROARRAY; VATER PAPILLA CARCINOMA; ADENOCARCINOMA; BILE DUCT TUMOR; CASE CONTROL STUDY; DNA MICROARRAY; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PANCREATICODUODENECTOMY; VATER PAPILLA;

ADENOCARCINOMA; AMPULLA OF VATER; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; COMMON BILE DUCT NEOPLASMS; DUODENUM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; SIALOGLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 16644366258     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.7.919     Document Type: Article

References (57)

1. Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF. Factors predictive of survival in ampullary carcinoma. Ann Surg 1998; 228:87-94.
2. Chareton B, Coiffic J, Landen S, Bardaxoglou E, Campion JP, Launois B. Diagnosis and therapy for ampullary tumors: 63 cases. World J Surg 1996; 20:707-12.
3. Allema JH, Reinders ME, van Gulik TM, et al. Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. Surgery 1995; 117:247-53.
4. Esposito I, Friess H, Buchler MW. Carcinogenesis of cancer of the papilla and ampulla: Pathophysiological facts and molecular biological mechanisms. Langenbecks Arch Surg 2001; 386:163-71.
5. Yamaguchi K, Enjoji M, Tsuneyoshi M. Pancreatoduodenal carcinoma: A clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol 1991; 47:148-54.
6. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53:549-54.
7. Howe JR, Klimstra DS, Cordon-Cardo C, Paty PB, Park PY, Brennan MF. K-ras mutation in adenomas and carcinomas of the ampulla of vater. Clin Cancer Res 1997; 3:129-33.
8. Chung CH, Wilentz RE, Polak MM, et al. Clinical significance of K-ras oncogene activation in ampullary neoplasms. J Clin Pathol 1996; 49:460-4.
9. Kalthoff H, Schmiegel W, Roeder C, et al. p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene. 1993; 8:289-98.
10. Park SH, Kim YI, Park YH, et al. Clinicopathologic correlation of p53 protein overexpression in adenoma and carcinoma of the ampulla of Vater. World J Surg 2000; 24:54-9.
11. Yoshida S, Todoroki T, Ichikawa Y, et al. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 1995; 55:2756-60.
12. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8:27-32.
13. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271:350-3.
14. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001; 7:3862-8.
15. Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000; 156:1821-5.
16. Wilentz RE, Geradts J, Maynard R, et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: Loss of intranuclear expression. Cancer Res 1998; 58:4740-4.
17. Moore PS, Orlandini S, Zamboni G, et al. Pancreatic tumours: Molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 2001; 84:253-62.
18. Burke CA, Beck GJ, Church JM, van Stolk RU. The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. Gastrointest Endosc 1999; 49:358-64.
19. Matsubayashi H, Watanabe H, Yamaguchi T, et al. Differences in mucus and K-ras mutation in relation to phenotypes of tumors of the papilla of vater. Cancer 1999; 86:596-607.
20. Wallace MH, Phillips RK. Preventative strategies for periampullary tumours in FAP. Ann Oncol 1999; 10:201-3.
21. Manley S, Mucci NR, De Marzo AM, Rubin MA. Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: The prostate specialized program of research excellence model. Am J Pathol 2001; 159:837-43.
22. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, van Heek T, Ashfaq R, Meyer R, Walter K, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 2002; 160:1239-49.
23. Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: Sea urchin fascin homolog and heat shock protein 47. Am J Clin Pathol 2002; 118:52-9.
24. Torbenson M, Wang J, Choti M, et al. Hepatocellular carcinomas show abnormal expression of fibronectin protein. Mod Pathol 2002; 15:826-30.
25. Adsay NV, Merati K, Andea A, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: Differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol 2002; 15:1087-95.
26. Luttges J, Zamboni G, Longnecker D, Kloppel G. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol 2001; 25:942-8.
27. Terada T, Ohta T, Sasaki M, Nakanuma Y, Kim YS. Expression of MUC apomucins in normal pancreas and pancreatic tumours. J Pathol 1996; 180:160-5.
28. Balague C, Gambus G, Carrato C, et al. Altered expression of MUC2, MUC4, and MUC5 mucin genes in pancreas tissues and cancer cell lines. Gastroenterology 1994; 106:1054-61.
29. Argani P, Rosty C, Reiter RE, et al. Discovery of new markers of cancer through serial analysis of gene expression: Prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001; 61:4320-4.
30. Iacobuzio-Donahue CA, Argani P, Hempen PM, Jones J, Kern SE. The desmoplastic response to infiltrating breast carcinoma: Gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res 2002; 62:5351-7.
31. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7:4060-6.
32. Samaras SE, Cissell MA, Gerrish K, Wright CV, Gannon M, Stein R. Conserved sequences in a tissue-specific regulatory region of the pdx-1 gene mediate transcription in Pancreatic beta cells: Role for hepatocyte nuclear factor 3 beta and Pax6. Mol Cell Biol 2002; 22:4702-13.
33. Donato R. S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001; 33:637-68.
34. Goldstein NS, Bassi D. Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold. Am J Clin Pathol 2001; 115:695-702.
35. Schwartz MA. Integrin signaling revisited. Trends Cell Biol 2001; 11:466-70.
36. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001; 61:5345-8.
37. Gress TM, Wallrapp C, Frohme M, et al. Identification of genes with specific expression in pancreatic cancer by cDNA representational difference analysis. Genes Chromosomes Cancer 1997; 19:97-103.
38. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62:407-13.
39. Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE. Exploring the host desmoplastic response to pancreatic carcinoma: Gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol 2002; 160:91-9.
40. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 2001; 280:460-5.
41. Koopmann J FN, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004; 13:487-91.
42. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998; 79:502-8.
43. Sung V, Gilles C, Murray A, et al. The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. Exp Cell Res 1998; 241:273-84.
44. Gillespie MT, Thomas RJ, Pu ZY, Zhou H, Martin TJ, Findlay DM. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 1997; 73:812-5.
45. Furger KA, Menon RK, Tuckl AB, Bramwelll VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001; 1:621-32.
46. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999; 39:246-61.
47. Tunio GM, Hirota S, Nomura S, Kitamura Y. Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer. Arch Pathol Lab Med 1998; 122:1087-90.
48. Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145:610-23.
49. Ue T, Yokozaki H, Kitadai Y, et al. Coexpression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998; 79:127-32.
50. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. Jama 2002; 287:1671-9.
51. Seidman JD. Osteopontin as a biomarker for ovarian cancer. Jama 2002; 287:3209; discussion 3209-10.
52. Ohmori R, Momiyama Y, Taniguchi H, et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003; 170:333-7.
53. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996; 93:136-40.
54. Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother 2000; 23:473-9.
55. Cahen DL, Fockens P, de Wit LT, Offerhaus GJ, Obertop H, Gouma DJ. Local resection or pancreaticoduodenectomy for villous adenoma of the ampulla of Vater diagnosed before operation. Br J Surg 1997; 84:948-51.
56. McCarthy DM, Maitra A, Argani P, et al. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: Mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol 2003; 11:238-43.
57. Maitra A, Adsay NV, Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003; 16:902-12.